[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 711, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 56, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2025, "totalPay": 2219569, "exercisedValue": 2948360, "unexercisedValue": 1465915}, {"maxAge": 1, "name": "Mr. Daniel J. Apel", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2025, "totalPay": 1044095, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  O'Brien J.D., PharmD", "age": 61, "title": "COO & Secretary", "yearBorn": 1964, "fiscalYear": 2025, "totalPay": 1051195, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James C. Hamilton M.D., MBA", "age": 46, "title": "Chief Medical Officer and Head of R&D", "yearBorn": 1979, "fiscalYear": 2025, "totalPay": 987213, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark M. Davis Ph.D.", "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce D. Given M.D.", "age": 71, "title": "Chief Medical Scientist", "yearBorn": 1954, "fiscalYear": 2025, "totalPay": 486308, "exercisedValue": 5934362, "unexercisedValue": 6159876}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 71, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Aaron  Tan", "title": "Head of Tax", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1767139200, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 64.64, "open": 66.0, "dayLow": 63.46, "dayHigh": 68.44, "regularMarketPreviousClose": 64.64, "regularMarketOpen": 66.0, "regularMarketDayLow": 63.46, "regularMarketDayHigh": 68.44, "payoutRatio": 0.0, "beta": 1.222, "trailingPE": 40.324997, "forwardPE": -14.950551, "volume": 23676640, "regularMarketVolume": 23676640, "averageVolume": 2750866, "averageVolume10days": 2255230, "averageDailyVolume10Day": 2255230, "bid": 64.32, "ask": 82.39, "bidSize": 26, "askSize": 2, "marketCap": 9034876928, "fiftyTwoWeekLow": 9.57, "fiftyTwoWeekHigh": 76.76, "allTimeHigh": 2925.0, "allTimeLow": 1.2, "priceToSalesTrailing12Months": 8.2814245, "fiftyDayAverage": 65.5854, "twoHundredDayAverage": 34.405174, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 8812604416, "profitMargins": 0.18540001, "floatShares": 121752388, "sharesOutstanding": 140032190, "sharesShort": 10790834, "sharesShortPriorMonth": 10234550, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0759, "heldPercentInsiders": 0.03805, "heldPercentInstitutions": 0.82831, "shortRatio": 4.02, "shortPercentOfFloat": 0.10520001, "impliedSharesOutstanding": 140032190, "bookValue": 4.137, "priceToBook": 15.595841, "lastFiscalYearEnd": 1759190400, "nextFiscalYearEnd": 1790726400, "mostRecentQuarter": 1767139200, "netIncomeToCommon": 202264992, "trailingEps": 1.6, "forwardEps": -4.31556, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 8.078, "enterpriseToEbitda": 27.062, "52WeekChange": 2.2449799, "SandP52WeekChange": 0.120657206, "quoteType": "EQUITY", "currentPrice": 64.52, "targetHighPrice": 110.0, "targetLowPrice": 35.0, "targetMeanPrice": 81.66667, "targetMedianPrice": 82.0, "recommendationMean": 1.76923, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 914710016, "totalCashPerShare": 6.532, "ebitda": 325649984, "totalDebt": 698163008, "quickRatio": 3.263, "currentRatio": 3.38, "totalRevenue": 1090980992, "debtToEquity": 124.074, "revenuePerShare": 7.975, "returnOnAssets": 0.14352, "returnOnEquity": 0.75496, "grossProfits": 1090980992, "freeCashflow": 170725872, "operatingCashflow": 339304992, "revenueGrowth": 104.613, "grossMargins": 1.0, "ebitdaMargins": 0.29849002, "operatingMargins": 0.15456, "financialCurrency": "USD", "symbol": "ARWR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "regularMarketChangePercent": -0.185648, "regularMarketPrice": 64.52, "epsCurrentYear": -3.08364, "priceEpsCurrentYear": -20.923323, "fiftyDayAverageChange": -1.0654068, "fiftyDayAverageChangePercent": -0.016244572, "twoHundredDayAverageChange": 30.114822, "twoHundredDayAverageChangePercent": 0.8752992, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "shortName": "Arrowhead Pharmaceuticals, Inc.", "longName": "Arrowhead Pharmaceuticals, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 756052200000, "postMarketChangePercent": 0.24799082, "postMarketPrice": 64.68, "postMarketChange": 0.16000366, "regularMarketChange": -0.120003, "regularMarketDayRange": "63.46 - 68.44", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2750866, "fiftyTwoWeekLowChange": 54.949997, "fiftyTwoWeekLowChangePercent": 5.741902, "fiftyTwoWeekRange": "9.57 - 76.76", "fiftyTwoWeekHighChange": -12.2400055, "fiftyTwoWeekHighChangePercent": -0.15945812, "fiftyTwoWeekChangePercent": 224.49799, "earningsTimestamp": 1770325200, "earningsTimestampStart": 1770325200, "earningsTimestampEnd": 1770325200, "earningsCallTimestampStart": 1770327000, "earningsCallTimestampEnd": 1770327000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 1.6, "epsForward": -4.31556, "corporateActions": [], "postMarketTime": 1770423830, "regularMarketTime": 1770411602, "exchange": "NMS", "messageBoardId": "finmb_203142", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "displayName": "Arrowhead Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2026-02-07"}]